Genesis IBRC India [GENESIS] vs Biocon [BIOCON] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Genesis IBRC India Ltd. wins in 2 metrics, Biocon Ltd. wins in 12 metrics, with 1 ties. Biocon Ltd. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Genesis IBRC India Ltd. | Biocon Ltd. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 57.89 | 71.84 | Genesis IBRC India Ltd. |
| Price-to-Book Ratio | 9.93 | 1.68 | Biocon Ltd. |
| Debt-to-Equity Ratio | 0.00 | 50.02 | Tie |
| PEG Ratio | N/A | 0.17 | N/A |
| EV/EBITDA | 26.95 | 19.22 | Biocon Ltd. |
| Profit Margin (TTM) | 2.36% | 3.59% | Biocon Ltd. |
| Operating Margin (TTM) | -11.05% | 7.63% | Biocon Ltd. |
| EBITDA Margin (TTM) | N/A | 7.63% | N/A |
| Return on Equity | 0.08% | 3.66% | Biocon Ltd. |
| Return on Assets (TTM) | 0.05% | 1.72% | Biocon Ltd. |
| Free Cash Flow (TTM) | $-3,000 | $17.18B | Biocon Ltd. |
| Dividend Yield | N/A | 0.26% | N/A |
| 1-Year Return | 365.12% | 17.90% | Genesis IBRC India Ltd. |
| Price-to-Sales Ratio (TTM) | 1,399.83 | 3.37 | Biocon Ltd. |
| Enterprise Value | $944.70M | $643.51B | Biocon Ltd. |
| EV/Revenue Ratio | 326.10 | 3.82 | Biocon Ltd. |
| Gross Profit Margin (TTM) | N/A | 67.91% | N/A |
| Revenue per Share (TTM) | $0 | $133 | Biocon Ltd. |
| Earnings per Share (Diluted) | $-0.18 | $4.87 | Biocon Ltd. |
| Beta (Stock Volatility) | N/A | 0.25 | N/A |
Genesis IBRC India Ltd. vs Biocon Ltd. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Genesis IBRC India Ltd. | 4.73% | -1.84% | -15.78% | -0.56% | 14.28% | 15.99% |
| Biocon Ltd. | -0.70% | 1.66% | -3.27% | 10.34% | 6.50% | 7.30% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Genesis IBRC India Ltd. | 365.12% | 779.33% | 1,160.05% | 482.04% | 4,600.00% | 4,600.00% |
| Biocon Ltd. | 17.90% | 71.09% | 5.03% | 250.57% | 603.49% | 1,357.39% |
Performance & Financial Health Analysis: Genesis IBRC India Ltd. vs Biocon Ltd.
| Metric | GENESIS | BIOCON |
|---|---|---|
| Market Information | ||
| Market Cap | ₹4.47B | ₹566.52B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 250 | 2,496,867 |
| 90 Day Avg. Volume | 317 | 3,790,310 |
| Last Close | ₹98.45 | ₹416.05 |
| 52 Week Range | ₹20.21 - ₹181.30 | ₹331.00 - ₹440.40 |
| % from 52W High | -45.70% | -5.53% |
| All-Time High | ₹184.90 (Nov 11, 2025) | ₹487.75 (Dec 21, 2020) |
| % from All-Time High | -46.76% | -14.70% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 0.09% |
| Quarterly Earnings Growth | N/A | 4.73% |
| Financial Health | ||
| Profit Margin (TTM) | 0.02% | 0.04% |
| Operating Margin (TTM) | -0.11% | 0.08% |
| Return on Equity (TTM) | 0.00% | 0.04% |
| Debt to Equity (MRQ) | 0.00 | 50.02 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹9.02 | ₹207.92 |
| Cash per Share (MRQ) | ₹5.26 | ₹45.84 |
| Operating Cash Flow (TTM) | ₹0 | ₹17.78B |
| Levered Free Cash Flow (TTM) | ₹35.05M | ₹10.13B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.26% |
| Last 12-Month Dividend | N/A | ₹1.00 |
Valuation & Enterprise Metrics Analysis: Genesis IBRC India Ltd. vs Biocon Ltd.
| Metric | GENESIS (Apr 24, 2026) | BIOCON (Apr 26, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 57.89 | 71.84 |
| Forward P/E | N/A | 38.56 |
| PEG Ratio | N/A | 0.17 |
| Price to Sales (TTM) | 1,399.83 | 3.37 |
| Price to Book (MRQ) | 9.93 | 1.68 |
| Market Capitalization | ||
| Market Capitalization | ₹4.47B | ₹566.52B |
| Enterprise Value | ₹944.70M | ₹643.51B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 326.10 | 3.82 |
| Enterprise to EBITDA | 26.95 | 19.22 |
| Risk & Other Metrics | ||
| Beta | N/A | 0.25 |
| Book Value per Share (MRQ) | ₹9.02 | ₹207.92 |
Financial Statements Comparison: Genesis IBRC India Ltd. vs Biocon Ltd.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | GENESIS (2025) | BIOCON (2025) |
|---|---|---|
| Revenue/Sales | 0 | 150.52B |
| Cost of Goods Sold | 0 | 51.98B |
| COGS % of Revenue | - | 34.5% |
| Gross Profit | 0 | 98.54B |
| Gross Margin | - | 65.5% |
| Research & Development | N/A | 6.34B |
| Operating Income (EBIT) | 35.05M | 16.26B |
| Operating Margin | - | 10.8% |
| EBITDA | 35.05M | 33.60B |
| EBITDA Margin | - | 22.3% |
| Pre-Tax Income | 35.05M | 18.87B |
| Pre-Tax Income % of Revenue | - | 12.5% |
| Income Tax | 0 | 4.57B |
| Income Tax % of Revenue | - | 3.0% |
| Net Income (Profit) | 35.05M | 14.29B |
| Profit Margin | - | 9.5% |
Balance Sheet & Liquidity Metrics
| Metric | GENESIS (2025) | BIOCON (2025) |
|---|---|---|
| Cash & Equivalents | 57,000 | 32.27B |
| Total Current Assets | 88.35M | 162.86B |
| Total Current Assets % of Revenue | - | 108.2% |
| Total Current Liabilities | 3.03M | 143.34B |
| Total Current Liabilities % of Revenue | - | 95.2% |
| Long-Term Debt | N/A | 129.45B |
| Long-Term Debt % of Revenue | - | 86.0% |
| Total Shareholders Equity | 85.33M | 277.13B |
| Retained Earnings | -83.06M | 189.59B |
| Retained Earnings % of Revenue | - | 126.0% |
| Property, Plant & Equipment | N/A | 4.32B |
Cash Flow Statement Comparison
| Metric | GENESIS (2025) | BIOCON (2025) |
|---|---|---|
| Operating Cash Flow | 0 | 17.78B |
| Operating Cash Flow % of Revenue | - | 11.8% |
| Capital Expenditures | N/A | -21.36B |
| Free Cash Flow | -3,000 | 17.18B |
| FCF Margin | - | 11.4% |
| Debt Repayment | N/A | -97.70B |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | GENESIS | BIOCON |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 45.25M | 1.62B |
| Float Shares | N/A | 583.07M |
| % Held by Insiders | 27.24% | 54.07% |
| % Held by Institutions | 0.00% | 24.88% |
| % Held by Public | 72.76% | 21.05% |
Dividend Analysis & Yield Comparison: Genesis IBRC India Ltd. vs Biocon Ltd.
| Metric | GENESIS | BIOCON |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹1.00 |
| Last 12-Month Dividend Yield | N/A | 0.26% |
| 3-Year Avg Annual Dividend | N/A | ₹1.33 |
| 3-Year Avg Dividend Yield | N/A | 0.36% |
| 3-Year Total Dividends | N/A | ₹4.00 |
| Ex-Dividend Date | N/A | Jul 04, 2025 |